Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and effectiveness of disease-modifying therapies after switching from natalizumab.

Autor: Zeineddine M; Inserm U1094, IRD U270, Univ. Limoges, CHU Limoges, EpiMaCT-Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, Omega Health, Limoges, France.; School of Pharmacy, Lebanese American University, Byblos, Lebanon., Al-Roughani R; Al-Amiri Hospital, Kuwait City, Kuwait., Farouk Ahmed S; Ibn Sina Hospital, Kuwait City, Kuwait., Khoury S; American University of Beirut Medical Center, Nehme and Therese Tohme Multiple Sclerosis Center, Beirut, Lebanon., El-Ayoubi N; American University of Beirut Medical Center, Nehme and Therese Tohme Multiple Sclerosis Center, Beirut, Lebanon., Al-Mahdawi A; Baghdad Medical City Teaching Hospital, Baghdad, Iraq., Al-Khabouri J; Department of Neurology, The Royal Hospital, Muscat, Oman., Al-Asmi A; Neurology Unit, Department of Medicine, College of Medicine and Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman., Chentouf A; Neurology Department, University Hospital Center, Oran, Algeria., Inshasi J; MS Department, Rashid Hospital and Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates., Gouider R; Department of Neurology, LR18SP03, Clinical Investigation Center 'Neurosciences and Mental Health,' Razi University Hospital-Manouba, Tunis, Tunisia., Mrabet S; Department of Neurology, LR18SP03, Clinical Investigation Center 'Neurosciences and Mental Health,' Razi University Hospital-Manouba, Tunis, Tunisia., Shalaby N; Neurology Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt., Massouh J; Neurology Institute and MS Center, Harley Street Medical Center, Abu Dhabi, United Arab Emirates., Mohamed Ramzy Hasan Mohamed F; Neurology Institute and MS Center, Harley Street Medical Center, Abu Dhabi, United Arab Emirates., Al-Hajje A; Faculty of Pharmacy, Lebanese University, Beirut, Lebanon.; National Institute of Public Health, Clinical Epidemiology and Toxicology (INSPECT-LB), Beirut, Lebanon., Salameh P; Faculty of Pharmacy, Lebanese University, Beirut, Lebanon.; National Institute of Public Health, Clinical Epidemiology and Toxicology (INSPECT-LB), Beirut, Lebanon.; School of Medicine, Lebanese American University, Byblos, Lebanon; Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus., Dimassi H; Faculty of Pharmacy, Lebanese University, Beirut, Lebanon.; National Institute of Public Health, Clinical Epidemiology and Toxicology (INSPECT-LB), Beirut, Lebanon.; School of Medicine, Lebanese American University, Byblos, Lebanon; Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus., Boumediene F; Inserm U1094, IRD U270, Univ. Limoges, CHU Limoges, EpiMaCT-Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, Omega Health, Limoges, France., Yamout B; Neurology Institute and MS Center, Harley Street Medical Center, Abu Dhabi, United Arab Emirates.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Jul; Vol. 30 (8), pp. 1026-1035. Date of Electronic Publication: 2024 Jul 26.